Vosevi Dosage

Generic name: SOFOSBUVIR 400mg, VELPATASVIR 100mg, VOXILAPREVIR 100mg
Dosage form: tablet, film coated
Drug class: Antiviral combinations

Medically reviewed by Drugs.com. Last updated on Mar 14, 2024.

Testing Prior to the Initiation of Therapy

Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with VOSEVI.

Recommended Dosage

The recommended dosage of VOSEVI is one tablet, taken orally, once daily with food. One tablet of VOSEVI contains 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir. Table 1 shows the recommended treatment regimen and duration based on patient population.

Table 1 Recommended Treatment Regimen and Duration in Adults Without Cirrhosis or With Compensated Cirrhosis (Child-Pugh A)
Genotype	Patients Previously Treated with an HCV Regimen Containing:	VOSEVI Duration
* In clinical trials, prior NS5A inhibitor experience included daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir. † In clinical trials, prior treatment experience included sofosbuvir with or without any of the following: peginterferon alfa/ribavirin, ribavirin, HCV NS3/4A protease inhibitor (boceprevir, simeprevir, or telaprevir).
1, 2, 3, 4, 5, or 6	An NS5A inhibitor*	12 weeks
1a or 3	Sofosbuvir without an NS5A inhibitor†	12 weeks

Renal Impairment

No dosage adjustment of VOSEVI is recommended in patients with any degree of renal impairment including patients on dialysis.

Moderate or Severe Hepatic Impairment

VOSEVI is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to higher exposures of voxilaprevir in these patients.

Frequently asked questions

More about Vosevi (sofosbuvir / velpatasvir / voxilaprevir)

Patient resources

Vosevi drug information

Professional resources

Related treatment guides

Hepatitis C

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

Review this drug

Images

Pill GSI 3 is Vosevi sofosbuvir 400 mg / velpatasvir 100 mg / voxilaprevir 100 mg — Vosevi sofosbuvir 400 mg / velpatasvir 100 mg / voxilaprevir 100 mg (GSI 3)

Vosevi Dosage

Testing Prior to the Initiation of Therapy

Recommended Dosage

Renal Impairment

Moderate or Severe Hepatic Impairment

Frequently asked questions

More about Vosevi (sofosbuvir / velpatasvir / voxilaprevir)

Patient resources

Professional resources

Related treatment guides

See also:

Epclusa

Harvoni

Ozempic

Mavyret

Sovaldi

Pegasys

Daclatasvir

Glecaprevir/pibrentasvir

Interferon alfa-2b

Ribavirin

Further information